# US 2026/0297176 A1 · Anti il-11 antibody

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0297176 A1
- Document ID: US20260297176A1
- Status: Published application
- Kind: A1
- Application number: 19/478,544
- Filed: 2024-04-24
- Published: 2026-10-01
- Earliest claimed: 2023-04-25
- Applicants: Vvb Bio Pte Ltd
- Inventors: Stuart Cook; Sebastian SCHAEFER
- Web page: https://patentgrep.com/patent/US20260297176A1

## CPC

- C07K 16/244: {Interleukins [IL]}
- G01N 33/57585: {involving compounds identifiable in body fluids}
- G01N 33/6869: {Interleukin}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/40: characterized by post-translational modification
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/567: Framework region [FR]
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- G01N 2333/5431: IL-11
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention is concerned with improved anti-IL-11 (Interleukin 11) antibodies, isolated nucleotide molecules encoding same, vectors, host cells, compositions, and uses of same.

## Claims

### Claim 1

An antibody that binds to human IL-11, the antibody comprising a heavy chain (HC) variable region (VH) sequence and a light chain (LC) variable region (VL) sequence,
(i) the heavy chain variable region sequence comprising the CDR3 and at least one additional CDR selected from the group consisting of:
(a) HC-CDR1 comprising the amino acid sequence GFSLSTSGMV (SEQ ID NO: 4) or a variant having one, two or three amino acid substitutions therein,
(b) HC-CDR2 comprising the amino acid sequence of IDWXGEK wherein ‘X’ is D (SEQ ID NO. 105) or E (SEQ ID NO: 123) or a variant having one or two amino acid substitutions therein, and
(c) HC-CDR3 comprising the amino acid sequence ARSGNYFEY (SEQ ID NO: 8) or a variant having one or two amino acid substitutions therein; and
(ii) the light chain variable region sequence comprising the CDR3 and at least one additional CDR selected from the group consisting of:
(a) LC-CDR1 comprising the amino acid sequence EDIYNA (SEQ ID NO: 13) or a variant having one or two amino acid substitutions therein,
(b) LC-CDR2 comprising the amino acid sequence DAN (SEQ ID NO: 15) or a variant having one amino acid substitution therein, and
(c) LC-CDR3 comprising the amino acid sequence QQYYDYPNT (SEQ ID NO: 17) or a variant having one or two amino acid substitutions therein.

### Claim 2 (depends on 1)

An antibody according to claim 1, wherein the heavy chain variable region sequence additionally comprises at least one of:
(a) FWR1 comprising the amino acid sequence QVILKESGPGMLQPSKTLSLTCSFS (SEQ ID NO: 3) or a sequence having at least 50% sequence identity therewith,
(b) FWR2 comprising the amino acid sequence VSWIRQPSGKSLEWLAA (SEQ ID NO: 5) or a sequence having at least 50% sequence identity therewith,
(c) FWR3 comprising the amino acid sequence YYNPSLKSRLTVSKDTSNTQVFLQITTVDIADTATYYC (SEQ ID NO: 7) or a sequence having at least 50% sequence identity therewith, and
(d) FWR4 comprising the amino acid sequence WGQGVIVXVSS (SEQ ID NO: 9) or a sequence having at least 50% sequence identity therewith.

### Claim 3 (depends on 1)

An antibody according to claim 1, wherein the light chain variable region sequence additionally comprises at least one of:
(a) FWR1 comprising the amino acid sequence DNQMTQSPASLSASLGETVTIECRTS (SEQ ID NO: 12) or a sequence having at least 50% sequence identity therewith,
(b) FWR2 comprising the amino acid sequence LAWYQQKPGKSPQLLIY (SEQ ID NO:
14) or a sequence having at least 50% sequence identity therewith,
(c) FWR3 comprising the amino acid sequence RLHIGVPSRFSGSGSGTQFSLKINSLQSEDVASYFC (SEQ ID NO: 16) or a sequence having at least 50% sequence identity therewith, and
(d) FWR4 comprising the amino acid sequence FGAGTKLELN (SEQ ID NO: 18) or a sequence having at least 50% sequence identity therewith.

### Claim 4 (depends on 1)

An antibody according to claim 1, wherein the HC-CDR2 has the sequence IDWEGEK (SEQ ID NO: 105).

### Claim 5

An antibody that binds to human IL-11, the antibody comprising a heavy chain (HC) variable region sequence and a light chain (LC) variable region sequence,
(i) the heavy chain variable region sequence comprising the CDR3 and at least one additional CDR selected from the group consisting of:
(a) HC-CDR1 comprising the amino acid sequence GYTFTSYV (SEQ ID NO: 22) or a variant having one, two or three amino acid substitutions therein,
(b) HC-CDR2 comprising the amino acid sequence IYPYNDDT (SEQ ID NO: 24) or a variant having one or two amino acid substitutions therein, and
(c) HC-CDR3 comprising the amino acid sequence TRERATYGDLAWFAY (SEQ ID NO: 26) or a variant having one or two amino acid substitutions therein; and
(ii) the light chain variable region sequence comprising the CDR3 and at least one additional CDR selected from the group consisting of:
(a) LC-CDR1 comprising the amino acid sequence ENIDSYGNSF (SEQ ID NO: 31) or a variant having one or two amino acid substitutions therein,
(b) LC-CDR2 comprising the amino acid sequence LAS or a variant having one amino acid substitution therein, and
(c) LC-CDR3 comprising the amino acid sequence QQNNEDPYT (SEQ ID NO: 35) or a variant having one or two amino acid substitutions therein, or
(i) the heavy chain variable region sequence comprising the CDR3 and at least one additional CDR selected from the group consisting of:
(a) HC-CDR1 comprising the amino acid sequence GFSLDNYN (SEQ ID NO: 40) or a variant having one, two or three amino acid substitutions therein,
(b) HC-CDR2 comprising the amino acid sequence IWTDGIT (SEQ ID NO: 42) or a variant having one or two amino acid substitutions therein, and
(c) HC-CDR3 comprising the amino acid sequence ARSYYYSLYYFDY (SEQ ID NO: 44) or a variant having one or two amino acid substitutions therein; and
(ii) the light chain variable region sequence comprising the CDR3 and at least one additional CDR selected from the group consisting of:
(a) LC-CDR1 comprising the amino acid sequence EDIYSN (SEQ ID NO: 49) or a variant having one or two amino acid substitutions therein,
(b) LC-CDR2 comprising the amino acid sequence DAH or a variant having one amino acid substitution therein, and
(c) LC-CDR3 comprising the amino acid sequence QQYDNYNT (SEQ ID NO: 53) or a variant having one or two amino acid substitutions therein, or
(i) the heavy chain variable region sequence comprising the CDR3 and at least one additional CDR selected from the group consisting of:
(a) HC-CDR1 comprising the amino acid sequence GFSLTNYH (SEQ ID NO: 58) or a variant having one, two or three amino acid substitutions therein,
(b) HC-CDR2 comprising the amino acid sequence MWIDGDT (SEQ ID NO: 60) or a variant having one or two amino acid substitutions therein, and
(c) HC-CDR3 comprising the amino acid sequence AREGLNWFAY (SEQ ID NO: 62) or a variant having one or two amino acid substitutions therein; and
(ii) the light chain variable region sequence comprising the CDR3 and at least one additional CDR selected from the group consisting of:
(a) LC-CDR1 comprising the amino acid sequence QGIDDY (SEQ ID NO: 67) or a variant having one or two amino acid substitutions therein,
(b) LC-CDR2 comprising the amino acid sequence DVT or a variant having one amino acid substitution therein, and
(c) LC-CDR3 comprising the amino acid sequence LQSYSTPYT (SEQ ID NO: 71) or a variant having one or two amino acid substitutions therein, or
(i) the heavy chain variable region sequence comprising the CDR3 and at least one additional CDR selected from the group consisting of:
(a) HC-CDR1 comprising the amino acid sequence GFSMSTSGMV (SEQ ID NO: 76) or a variant having one, two or three amino acid substitutions therein,
(b) HC-CDR2 comprising the amino acid sequence IDWDGEK (SEQ ID NO: 78) or a variant having one or two amino acid substitutions therein, and
(c) HC-CDR3 comprising the amino acid sequence ARSGNYFDY (SEQ ID NO: 80) or a variant having one or two amino acid substitutions therein; and
(ii) the light chain variable region sequence comprising the CDR3 and at least one additional CDR selected from the group consisting of:
(a) LC-CDR1 comprising the amino acid sequence EDIYNG (SEQ ID NO: 85) or a variant having one or two amino acid substitutions therein,
(b) LC-CDR2 comprising the amino acid sequence DAN or a variant having one amino acid substitution therein, and
(c) LC-CDR3 comprising the amino acid sequence QQYYDYPNT (SEQ ID NO: 89) or a variant having one or two amino acid substitutions therein.

### Claim 6 (depends on 5)

An antibody according to claim 5, wherein the heavy chain variable region sequence additionally comprises at least one of:
(a) FWR1 comprising the amino acid sequence EVHLQQSGPELVKPGASVKMSCKAS (SEQ ID NO: 21) or a sequence having at least 50% sequence identity therewith,
(b) FWR2 comprising the amino acid sequence IHWVKQRPGQGLEWIGN (SEQ ID NO: 23) or a sequence having at least 50% sequence identity therewith,
(c) FWR3 comprising the amino acid sequence NYNEKFKGKATLTSDKSSSTAYMELSSLTSEESAVYFC (SEQ ID NO: 25) or a sequence having at least 50% sequence identity therewith, and
(d) FWR4 comprising the amino acid sequence WGQGTLVTVSA (SEQ ID NO: 27) or a sequence having at least 50% sequence identity therewith.

### Claim 7 (depends on 5)

An antibody according to claim 5, wherein the light chain variable region sequence additionally comprises at least one of:
(a) FWR1 comprising the amino acid sequence NIVLTQSPASLAVSLGQRATISCRAS (SEQ ID NO: 30) or a sequence having at least 50% sequence identity therewith,
(b) FWR2 comprising the amino acid sequence MHWYQQKPGQPPKLLIY (SEQ ID NO: 32) or a sequence having at least 50% sequence identity therewith,
(c) FWR3 comprising the amino acid sequence ILESGVPARFSGSGSRTDFTLTIDPVEADDAATYYC (SEQ ID NO: 34) or a sequence having at least 50% sequence identity therewith, and
(d) FWR4 comprising the amino acid sequence FGGGTKLEIK (SEQ ID NO: 36) or a sequence having at least 50% sequence identity therewith.

### Claim 8

(canceled)

### Claim 9 (depends on 5)

An antibody according to claim 5, wherein the heavy chain variable region sequence additionally comprises at least one of:
(a) FWR1 comprising the amino acid sequence QVQLKESGPGLVQPSQTLSLTCTVS (SEQ ID NO: 39) or a sequence having at least 50% sequence identity therewith,
(b) FWR2 comprising the amino acid sequence VHWVRQPTGGGLEWLGG (SEQ ID NO: 41) or a sequence having at least 50% sequence identity therewith,
(c) FWR3 comprising the amino acid sequence DYTSPLRSRLSISRDTSKSQVFLKMKSLQTEDIATYYC (SEQ ID NO: 43) or a sequence having at least 50% sequence identity therewith, and
(d) FWR4 comprising the amino acid sequence WGQGVMVTVSS (SEQ ID NO: 45) or a sequence having at least 50% sequence identity therewith.

### Claim 10 (depends on 5)

An antibody according to claim 5, wherein the light chain variable region sequence additionally comprises at least one of:
(a) FWR1 comprising the amino acid sequence DIQMTQSPASLSASLGETVTIECRAS (SEQ ID NO: 48) or a sequence having at least 50% sequence identity therewith,
(b) FWR2 comprising the amino acid sequence LAWYQQKPGDSPQLLIY (SEQ ID NO: 50) or a sequence having at least 50% sequence identity therewith,
(c) FWR3 comprising the amino acid sequence RLAEGVPSRFSGSGSGTQYSLKINSLHSEDVASYFC (SEQ ID NO: 52) or a sequence having at least 50% sequence identity therewith, and
(d) FWR4 comprising the amino acid sequence FGVGTKLDLK (SEQ ID NO: 54) or a sequence having at least 50% sequence identity therewith.

### Claim 11

(canceled)

### Claim 12 (depends on 5)

An antibody according to claim 5, wherein the heavy chain variable region sequence additionally comprises at least one of:
(a) FWR1 comprising the amino acid sequence QVQLKESGPGLVQPSQTLSLTCTVS (SEQ ID NO: 57) or a sequence having at least 50% sequence identity therewith,
(b) FWR2 comprising the amino acid sequence VHWVRQPPGKGLEWMGV (SEQ ID NO: 59) or a sequence having at least 50% sequence identity therewith,
(c) FWR3 comprising the amino acid sequence SYNSALRSRLSISRDTSKSQVFLKMSSLQTEDTATYYC (SEQ ID NO: 61) or a sequence having at least 50% sequence identity therewith, and
(d) FWR4 comprising the amino acid sequence WGRGTLVTVSS (SEQ ID NO: 63) or a sequence having at least 50% sequence identity therewith.

### Claim 13 (depends on 5)

An antibody according to claim 5, wherein the light chain variable region sequence additionally comprises at least one of:
(a) FWR1 comprising the amino acid sequence DIQMTQSPASLSVSLEEVVTITCKAS (SEQ ID NO: 66) or a sequence having at least 50% sequence identity therewith,
(b) FWR2 comprising the amino acid sequence LSWYQQKPGKSPQLLIS (SEQ ID NO: 68) or a sequence having at least 50% sequence identity therewith,
(c) FWR3 comprising the amino acid sequence SLADGVPSRFSGSRSGTQYSLKISRPQVDDSGIYYC (SEQ ID NO: 70) or a sequence having at least 50% sequence identity therewith, and
(d) FWR4 comprising the amino acid sequence FGAGTKLELK (SEQ ID NO: 72) or a sequence having at least 50% sequence identity therewith.

### Claim 14

(canceled)

### Claim 15 (depends on 5)

An antibody according to claim 5, wherein the heavy chain variable region sequence additionally comprises at least one of:
(a) FWR1 comprising the amino acid sequence QVTLKESGPGMLQPSKTVSLTCSFS (SEQ ID NO: 75) or a sequence having at least 50% sequence identity therewith,
(b) FWR2 comprising the amino acid sequence VSWIRQPSGKSLEWLAA (SEQ ID NO: 77) or a sequence having at least 50% sequence identity therewith,
(c) FWR3 comprising the amino acid sequence YYNPSLKSRLTVSKDTSNTQVFLKISSVDIADSATYYC (SEQ ID NO: 79) or a sequence having at least 50% sequence identity therewith, and
(d) FWR4 comprising the amino acid sequence WGQGVMVTVSS (SEQ ID NO: 81) or a sequence having at least 50% sequence identity therewith.

### Claim 16 (depends on 5)

An antibody according to claim 5, wherein the light chain variable region sequence additionally comprises at least one of:
(a) FWR1 comprising the amino acid sequence DIQMTQSPASLSASLGETVTIECRAS (SEQ ID NO: 84) or a sequence having at least 50% sequence identity therewith,
(b) FWR2 comprising the amino acid sequence LVWYQQKPGKSPQLLIY (SEQ ID NO: 86) or a sequence having at least 50% sequence identity therewith,
(c) FWR3 comprising the amino acid sequence RLHTGVPSRFSGGGSGTQYSLKINSLQSEDVASYFC (SEQ ID NO: 88) or a sequence having at least 50% sequence identity therewith, and
(d) FWR4 comprising the amino acid sequence FGAGTKLELK (SEQ ID NO: 90) or a sequence having at least 50% sequence identity therewith.

### Claim 17

(canceled)

### Claim 18 (depends on 1)

An antibody according to claim 1, wherein the heavy chain variable region sequence comprises all three of the CDR1, CDR2 and CDR3.

### Claim 19 (depends on 1)

An antibody according to claim 1, wherein the light chain variable region sequence comprises all three of the CDR1, CDR2 and CDR3.

### Claim 20 (depends on 1)

An antibody according to claim 1, wherein it comprises a heavy chain having the sequence of SEQ ID NO: 99 and a light chain having the sequence of SEQ ID NO: 94.

### Claim 21 (depends on 1)

An antibody according to claim 1, wherein it comprises a heavy chain having the sequence of SEQ ID NO: 100 and a light chain having the sequence of SEQ ID NO: 94.

### Claim 22

An antibody that binds to human IL-11, wherein the antibody binds to a discontinuous epitope on human IL-11, wherein the discontinuous epitope comprises amino acid residues:
(a) R30, S41, T95, R98, S145, and R146;
(b) R30, S41, R138, R146, R190, K196, T197, and R198;
(c) R30, T46, R135, S145, R146, R190, and K196;
(d) S48, T53, R54, R96, R98, S103, R106, H107, T128, R132, R138, R139, H182, and R190; or
(e) T46, T54, T95, R112, H182, and R190;
when numbered in accordance with SEQ ID NO: 125.

### Claim 23 (depends on 1)

An antibody according to claim 1, wherein it is a monoclonal antibody.

### Claim 24 (depends on 1)

An antibody according to claim 1, wherein it is chemically or biologically modified.

### Claim 25 (depends on 24)

An antibody according to claim 24, wherein it is glycosylated, PEGylated or HESylated.

### Claim at position 26

26-41. (canceled)

### Claim 42 (depends on 1)

A method comprising the steps of:
i) reacting an antibody according to claim 1, specific to the protein with serum from a patient; and
ii) detecting any antibody-antigen binding reaction.
